Drug Database
OM

omeprazole

✓ Approved

Santarus, Inc. · ATP4A · 小分子

什么是 omeprazole?

omeprazole 是一种小分子,由Santarus, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

公司Santarus, Inc.
药物类别小分子
分子靶点ATP4A
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

omeprazole 作用于 1 个分子靶点:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

omeprazole 针对 3 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersDuodenal ulcer✓ Approved
Gastrointestinal disordersGastric ulcer✓ Approved
Gastrointestinal disordersGastrooesophageal reflux disease✓ Approved

相关研究文献

PubMedMethods in molecular biology (Clifton, N.J.)2026-11-19

Robot Navigation for Precise Puncture of Solid Tumors.

An Chao C, Zuo Mengxuan M, Zhou Soujun S, Xu Changjiang C et al.

With the advent of precision medicine, solid tumor puncture treatment has shifted from traditional manual techniques to a new, personalized era of robotic navigation. The incidence of lung, liver, and other cancers continues to increase, creating an urgent need for minimally invasive interventions. However, due to challenges such as respiratory movement and small lesion size, traditional methods still struggle to achieve precise, single-attempt puncture. Robotic navigation systems that integrate multimodal image fusion, AI-based path planning, and intelligent control algorithms have been developed to address these limitations. This paper reviews the key technologies and application progress of solid tumor puncture robot navigation systems to offer a new perspective on the precise treatment of solid tumors and highlight their potential to improve clinical outcomes.

PMID 43052665
阅读全文 →
PubMedNature biomedical engineering2026-11-19

Designer mucin-responsive nanomedicine for enhanced solid tumour penetration and therapy.

Yu Na N, Gong Ningqiang N, Liu Juan J, Zhong Haiping H et al.

While nanomedicines hold great promise for solid tumour therapy, their penetration and access to tumour cells is limited by large glycosylated proteins called mucins that are enriched in the tumour microenvironment. Here we show that mucins induce the disassembly of self-assembled mPEG-polyester micellar nanoparticles into smaller unimers. Leveraging this finding, we designed a mucin-responsive, paclitaxel-conjugated nanomedicine (mrPNM) whose unimers are capable of escaping the mucin-binding barrier. Following intravenous injection, this designer mucin-responsive nanomedicine exhibited markedly deeper penetration than the mucin-nonresponsive nanomedicine and albumin, resulting in 3.9- and 1.5-fold increases in tumour cell delivery, respectively, in a pancreatic mouse tumour model. The mrPNMs also achieved superior tumour growth inhibition compared to both the mucin-nonresponsive nanomedicine and Abraxane, the FDA-approved nanoparticle albumin-bound paclitaxel, in three solid tumour models. The mucin-responsive nanomedicine platform could provide a general strategy for improving the treatment of solid tumours.

PMID 43052497
阅读全文 →
PubMedNature communications2026-11-19

Kinetic acceleration of phosphate remediation in dilute aquatic environments via photovoltaic-driven solid-state electrolyte electrocoagulation.

Liu Shan S, Gu Xiaosong X, Chen Zhongxin Z, Liang Jiaxiang J et al.

The kinetic limitations of reclaiming low-level orthophosphate (PO43-) in low-conductivity natural water bodies impede the in-depth remediation of anthropogenic eutrophication. Conventional adsorption and electrocoagulation (EC) methods are hindered by excessive chemical reagent consumption, high electrical energy demand, and substantial metal electrode consumption. Here, we present a solid-state electrolyte electrocoagulation (SEE) system that employs an interfacial coupling strategy to integrate dynamic ion enrichment with in situ anodic coagulation. By concentrating PO43- at the solid-state electrolyte interface, the system overcomes inherent mass-transport constraints and enhances ion conductivity in dilute media. This localized concentration gradient accelerates apparent reaction kinetics, achieving a removal rate of 0.197 mg/L·min, minimizing energy consumption to 0.0325 kWh/g P and iron consumption to 3.829 g/g P. Consequently, SEE enables efficient, one-step purification below strict regulatory thresholds ( ≤ 0.02 mg/L, China's Class I Surface Water Environmental Quality Standard). Validated as a photovoltaic-integrated, boat-mounted unit, this approach offers a robust decentralized solution for natural waters, with techno-economic and life cycle assessments confirming its economic viability and low environmental footprint.

PMID 43052295
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Solid-Phase Capture of Phage for Combinatorial Chemical Diversification of Peptide Libraries.

Hu Che-Wei CW, Ji Xinjian X, Brantschen Frédéric F, Heinis Christian C

The chemical and structural diversity of peptide phage or mRNA-display libraries can be expanded by chemical modification, such as with cyclization reagents or by incorporation of unnatural amino acids, but the number of different non-natural building blocks introduced has been modest so far. To expand the chemical diversity in peptide display libraries, we developed a strategy for efficient parallel chemical diversification of phage display libraries based on capturing phage on a solid support via a polyhistidine tag and chemical modification. We applied chemically diverse building blocks in a 96-well format that allowed high-throughput experimentation, including parallel phage panning. Selections against the oncology target MCL-1 identified binders containing unnatural building blocks that were important for binding, such as thienylpyridine. This demonstrated the effectiveness of the approach and emphasized the advantages of an increased chemical diversity. This strategy may be particularly attractive for generating short peptide-based ligands, where the number of combinations based on proteinaceous amino acids is limited, for generating membrane-permeable peptides required for oral application or intracellular targeting.

PMID 43053394
阅读全文 →
PubMedBMC cancer2026-11-19

Impact of Charlson Comorbidity Index conditions on one-year survival in patients with breast cancer: a Danish population-based cohort study.

Körmendiné Farkas Dóra D, Horváth-Puhó Erzsébet E, Ahern Thomas P TP, Vandenbroucke Jan P JP et al.

Breast cancer is the most frequently diagnosed malignancy in women. The Charlson Comorbidity Index (CCI) is a widely used tool for quantifying multimorbidity. As the population ages, breast cancer incidence and comorbidity prevalence are expected to grow. We therefore investigated the absolute and relative impact of the CCI conditions on 1-year mortality in Danish patients with breast cancer. In this population-based cohort study, we identified women with breast cancer from 1987 to 2022 using the Danish Cancer Registry. We estimated 1-year mortality using the Kaplan-Meier method and adjusted hazard ratios (aHRs) using Cox proportional hazards regression. Analyses were stratified by calendar year, cancer stage, and age at diagnosis. Among 146,397 women with breast cancer (median age: 63.4 years; localized stage: 51%), 27.5% had at least one CCI condition. The most prevalent conditions were chronic pulmonary disease (6.5%), non-metastatic solid tumors (6.0%), and cerebrovascular disease (5.6%). One-year mortality was highest in women with dementia (27.3%), congestive heart failure (21.7%), and metastatic solid tumors (20.4%). All CCI conditions, except connective tissue disease, were associated with elevated mortality. The highest hazard ratios were observed for AIDS (aHR: 4.54 [95% confidence interval (CI): 1.46-14.1]), moderate to severe liver disease (aHR: 3.53 [95% CI: 2.70-4.61]), and metastatic solid tumors (aHR: 2.26 [95% CI: 1.92-2.66]). Mortality declined over time, with an impact of CCI conditions across time periods seen for absolute but not for relative risks. The impact of comorbidities was greater among younger women and those with localized or regional spread cancer. Most CCI conditions were associated with elevated 1-year mortality in Danish patients with breast cancer, although absolute mortality declined substantially over time. Our findings provide updated estimates of the prognostic impact of individual CCI conditions in patients with breast cancer.

PMID 43052848
阅读全文 →
PubMedDalton transactions (Cambridge, England : 2003)2026-11-19

Alkyl-chain-functionalized Cu(I)-Xantphos complexes exhibiting packing-controlled solid-state emission and efficient TADF.

Zhang Kai K, Wang Ran R, Sun Hao H, Sun Zhe Z et al.

With excellent photophysical properties, facile synthesis, and low cost, copper(I) iodide complexes have become an important class of luminescent materials for various applications. However, the field still faces challenges in achieving precise modulation of luminescence properties through simple structural modifications. In this work, a series of copper(I) halide complexes based on the [CuI(1-R-imidazole)(Xantphos)] structure was successfully synthesized, enabling precise tuning of photophysical properties by systematically varying the alkyl chain length. As the alkyl chains lengthen, the emission wavelength gradually blue-shifts, accompanied by a concurrent increase in quantum yield in the solid state. Collective theoretical and experimental evidence shows that these compounds possess nearly identical molecular structures, conformations, and orbital distributions, but exhibit systematic variations in crystal packing patterns induced by the steric hindrance of their alkyl chains. Consequently, they serve as an excellent model system for elucidating how crystal packing arrangements govern the efficient blue emission of copper-iodine hybrids. This work introduces a rational molecular engineering strategy for the design of high-performance copper(I) iodide luminescent materials, thereby advancing the development of functional luminescent materials.

PMID 43053741
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多omeprazole